Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Double-Blind Randomized Vehicle-Controlled Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
2018-003713-18Phase 3Completed
- Sponsor
- Incyte
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Ruxolitinib cream with Vehicle (placebo) cream (2 arms). Primary endpoint: Proportion of participants achieving IGA-TS at Week 8. Started Mar 2019; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-003713-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003713-18.